“Pfizer said on Thursday its oral drug helped restore skin color in patients with a common form of vitiligo in ​two late-stage trials…

The U.S. drugmaker was testing Litfulo in patients with nonsegmental vitiligo, the most common type of the ​disease, which causes patches of skin to lose pigment.

Pfizer said ​both studies showed significantly more patients treated with the ⁠drug achieved at least a 75% improvement in facial repigmentation and ​at least a 50% improvement in total-body repigmentation after 52 weeks ​compared with those given placebo.”

From Reuters.